Please login to the form below
Patent exclusivity
This page shows the latest Patent exclusivity news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly shares adjusted financial guidance for 2023
its loss of patent exclusivity and no expected COVID-19 antibody revenue.
Latest news
-
Democrats in the US agree plan to curb drug prices
Under the proposal, most drugs would retain patent exclusivity for nine years before negotiations could start, 12 years for biologics.
-
Amarin shares tumble following Vascepa patent loss
The patent ruling only applies to Vascepa’s US patent exclusivity, with Amarin clarifying that its patents elsewhere in the world still stand.
-
UPDATED: Gilead drops remdesivir’s orphan drug designation
Gilead had maintained that at the time that it had filed for the designation – which awards companies with patent exclusivity for seven years – the coronavirus outbreak was nowhere near the level ... Along with patent exclusivity, orphan drug
-
China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir
Raises concerns over patent exclusivity in the country. UPDATED 5 MARCH 2020: BrightGene has since been censured by the Shanghai Stock Exchange (SSE) for making misleading claims and disclosing inaccurate information ... The news reflects a larger issue
-
Biologic patent exclusivity scrapped in new US trade deal
The negotiations between the US, Mexico and Canada have reached an agreement to scrap patent exclusivity for biologics, meaning that each country can determine its own rules. ... In the past, the US has pushed to have its exclusivity rules applied to
More from news
Approximately 1 fully matching, plus 59 partially matching documents found.
Latest Intelligence
-
Piloting a route to the biosimilars opportunities in Europe
By 2019, more than 14 innovative biological products had lost their orphan designation market exclusivity, and by 2029 another 34 innovative biological products will join them. ... Once that formula’s patent and market exclusivity expires, competing
-
The impact of COVID-19 on clinical trials
Delays in clinical trials will also likely translate into delays in launch timelines, which may result in shorter periods of patent exclusivity post-launch and lower revenue forecasts.
-
Interview: Trevor Smith, Takeda
Major products were about to lose, or had just lost, their patent exclusivity.”. ... For Nycomed this meant loss of exclusivity (LOE) on its blockbuster gastroinestinal drug pantoprazole and the consequent need to reorganise its business.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Three strategies for managing loss of exclusivity successfully
2. “Price decay after loss of brand exclusivity”. 3. These are just three headlines that come up when you Google “drug patent expiry”. ... 4. It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for
-
Three strategies for managing loss of exclusivity successfully
Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. ... It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for drug
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
